HS Connect Launches “The Healing Space,” A Mental Health Hub for HS Patients

May 2, 2025

Awareness Gap: Many HS Patients Don’t Know About New Treatment Options

April 1, 2025

Incyte’s Povorcitinib Hits Primary Endpoints in Phase 3 HS Studies

March 17, 2025

Delving Into New Two-year Bimekizumab (Bimzelx, UCB) Data in Hidradenitis Suppurativa (HS) With Christopher Sayed, MD

March 10, 2025

New Two-year Data: Bimekizumab Provides Sustained Disease Control in HS

February 13, 2025

News You and Your Patients Can Use: New Dosing Option for UCB’s Bimekizumab Now Commercially Available for PsO, PsA, and HS

January 16, 2025

A Future Physician’s Journey With HS

December 2, 2024

Meeting Unmet Needs in HS With UCB’s Dr. Jeff Stark

November 25, 2024

What Does the Approval of Bimekizumab-bkzx (Bimzelx, UCB) Mean for the HS Community?

November 22, 2024

U.S. FDA Approves Bimekizumab-bkzx (Bimzelx, UCB) for HS

November 20, 2024

UNC Researchers Score Grant to Study Genetics of HS

October 11, 2024

HS Pipeline Watch: First Patient Dosed in Phase 2 Trial of AVTX-009; Topline Data Expected in 2026

October 8, 2024